

Date: June 4, 2025

Dr Ashleys Limited reaffirms its commitment to help mitigate the reported outbreak of COVID-19.

Thailand Business News reported on May 29, 2025 that a total of 187,031 Covid 19 cases and 46 deaths from January to mid-May. Singapore has also reported a weekly increase of Covid-19 cases from 11,000 to 14,200 cases with average daily hospitalizations from 103 to 133 patients.

This serious new wave of infections is primarily affecting individuals aged between 30 to 39. Health authorities in Thailand have advised citizens to wear face masks and use antigen test kits (ATK) if they develop symptoms such as fever, cough, or fatigue. The XEC variant, a descendant of Omicron, is spreading rapidly, with infections skyrocketing and vulnerable groups being most at risk.

Response from Dr. Ashleys to the COVID-19 Update: Thailand and Singapore

In light of the recent surge in COVID-19 cases in Thailand and Singapore, Dr. Ashleys reaffirms its unwavering commitment to public health and safety. As a leading global pharmaceutical company, we recognize the critical role we play in combating this pandemic.

At Dr. Ashleys, we are dedicated to producing high-quality Active Pharmaceutical Ingredients (APIs) for COVID-19 medications. Our primary focus is to ensure that local pharmaceutical companies have the necessary resources to manufacture effective treatments for COVID-19. We understand the urgency of the situation and are committed to doing everything within our power to support our customers. Through our strategically positioned 80 distributors throughout Asia, Africa and Eastern Europe, we are confident that we can deliver these essential drugs to those in need.

Under the visionary leadership of Dr. Kanans Visvanants FRSC, a second-generation pharmaceutical and chemical engineer, the company revolutionized the industry by significantly reducing the cost of manufacturing generic and patented drugs. With 15 manufacturing patents, the company provides over 300 million annual medical doses to the world's disease epicenters, addressing both non-communicable diseases and infectious diseases.

Dr. Ashleys Limited is a global pharmaceutical company, together with its subsidiaries, dedicated to the development and manufacturing of specialized and complex active pharmaceutical ingredients (APIs) and Orphan Drugs for Rare Diseases. The company's expertise spans across various critical health areas, including malaria, cancer,

gastrointestinal disorders, acute respiratory infections, COVID-19, dengue fever, tuberculosis, and other infectious diseases.

####

For more information contact:

William Keegan
President, CEO
Capital Formation Marketing, LLC.
capitalformationmarketing.com

8 Bridle Path
Avon, Connecticut, 06001, USA
Phone: (516) 435-8365
wkeegan@cfmct.com